Slideshow

Treat-to-Target in RA Hits the Bull’s-eye

Recent findings allay concerns about increased costs and rates of adverse events related to TTT strategies.

Reference1. Solomon DH, Yu Z, Katz JN, et al. Adverse events and resource use before and after treat to target in rheumatoid arthritis: a post-hoc analysis of a randomized controlled trial. Arthritis Care Res. 2018 Sep 17. doi: 10.1002/acr.23755. [Epub ahead of print]

Related Videos
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Comparing Treatment Options for Psoriatic Arthritis with Philip Mease, MD
Considering Viral Infections in Patients With Rheumatic Disease With Leonard Calabrese, DO
Leonard H. Calabrese, DO, Professor of Medicine and Vice Chair, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University
Alvin Wells, MD, PhD: Making Informed Treatment Decisions With New Testing Strategies
Alvin Wells, MD, PhD
Upcoming Research in PsA, AxSpa, with Philip Mease, MD
Philip Mease, MD, Clinical Professor, University of Washington School of Medicine and Director, Rheumatology Research, Swedish Medical Center
Related Content
Claire Immediato Daien, professor, rheumatology, Centre Hospitalier Universitaire de Montpellier, France
October 23rd 2024

Multimorbidity Screening Reduced Hospitalizations in Patients With Rheumatic Diseases

Victoria Johnson
Emerging Agents in the Treatment of Rheumatic Diseases
October 2nd 2023

Emerging Agents in the Treatment of Rheumatic Diseases

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR Philip J. Mease, MD
Laura YL Kummer, Doctorate Student / Research Assistant. Department of Immunopathology, Sanquin Research
October 22nd 2024

Methotrexate May Lower Vaccine Response in Patients With RA

Victoria Johnson
Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis
August 31st 2023

Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR John B. Boone, MD, FACR Madelaine Feldman MD, FACR
James Helliwell, MD, cofounder and CEO, Eupraxia
October 18th 2024

EP-104IAR Phase 2 Data Shows Potential for Knee Osteoarthritis Pain

Victoria Johnson
Lauma Ievina, PhD candidate, The Institute of Microbiology and Virology of the Riga Stradiņš University Science Hub, Latvia
October 18th 2024

Study Identifies Gut Microbiome Makeup, Diversity Differences in People With Fibromyalgia

Victoria Johnson
© 2024 MJH Life Sciences

All rights reserved.